Raptor Pharmaceutical Co. plans to launch Quinsair inhaled levofloxacin inhalation solution in Europe and Canada by mid-2016, the company said after announcing that it has agreed to pay Tripex Pharmaceuticals $68.4 million upfront and up to $350 million in milestone payments and royalties to acquire global rights to the product. Quinsair (formerly Aeroquin) was … [Read more...] about Raptor Pharmaceutical acquires Quinsair levofloxacin inhalation solution
News
Phase 3 data show Stiolto/Spiolto Respimat improves quality of life
Boehringer Ingelheim has published new data from the two OTEMTO Phase 3b trials of the Stiolto/Spiolto Respimat tiotropium/olodaterol SMI for the treatment of COPD. The data show that the inhaler produced clinically meaningful improvements in quality of life versus placebo as measured by the St. George's Respiratory Questionnaire (SRGQ). The soft mist inhaler is … [Read more...] about Phase 3 data show Stiolto/Spiolto Respimat improves quality of life
Cirrus Pharmaceuticals hires Andrew Hamer as VP R&D
Cirrus Pharmaceuticals announced that it has hired Andrew Hamer as VP R&D. Hamer was most recently Senior Director of R&D Operations at GSK's dermatology subsidiary Stiefel. He also has experience in OINDP development at Cardinal, Sanofi, and Covance. Cirrus, based in Research Triangle Park, NC, was acquired by Kemwell in 2013. It offers inhalation and nasal … [Read more...] about Cirrus Pharmaceuticals hires Andrew Hamer as VP R&D
MannKind appoints Raymond Urbanski as Chief Medical Officer
MannKind Corporation has announced the appointment of former Mylan CMO Raymond Urbanski as its Chief Medical Officer. Urbanski has also held positions at Metabolix, Pfizer, and Suntory, with experience in drug development for oncology, rheumatology, cardiology, endocrinology, and immunology. MannKind CEO Hakan Edstrom commented, "Dr. Urbanski is a terrific addition … [Read more...] about MannKind appoints Raymond Urbanski as Chief Medical Officer
Pulmatrix announces plans for Phase 1 trial of inhaled anti-fungal for CF, BE study for LAMA
According to an update from Pulmatrix, the company has enough capital to fund development of its inhaled drug portfolio through the middle of 2017, and its plans over the next year and a half include the initiation of a Phase 1 trial of PUR1900 for the treatment of cystic fibrosis, and a pharmacokinetic bioequivalence study of PUR0200 for the treatment of COPD. … [Read more...] about Pulmatrix announces plans for Phase 1 trial of inhaled anti-fungal for CF, BE study for LAMA
Novartis launches Sequadra indacaterol/glycopyrronium inhaler in India
Novartis Healthcare Private Limited has announced the launch of the Sequadra indacaterol/glycopyrronium (110mcg/50mcg) DPI for the treatment of COPD in India. Novartis's indacaterol/glycopyrronium DPI is marketed in Europe and Japan as Ultibro Breezhaler. Novartis filed an NDA for the inhaler with the FDA in late 2014. Novartis India Country President Jawed Zia … [Read more...] about Novartis launches Sequadra indacaterol/glycopyrronium inhaler in India
Cipla announces the upcoming launch of the Synchrobreathe inhaler
Cipla has announced that it will launch the Synchrobreathe breath-actuated inhaler, which the company says requires low inspiratory flow to actuate, by the end of 2015. Company executives discussed the new inhaler at the 2015 South Africa Thoracic Society Conference. Cipla Global Head of Respiratory Frank Pieters commented, “Simple and intuitive, Synchrobreathe is … [Read more...] about Cipla announces the upcoming launch of the Synchrobreathe inhaler
Turing Pharmaceuticals announces that it has raised $90 million
Turing Pharmaceuticals, which is developing intranasal oxytocin for several indications has announced the completion of $90 million Series A financing round led by its Founder and CEO, Martin Shkreli. According to Turing, "the financing included participation from multiple preeminent institutional equity investors," but none were named. Retrophin divested intranasal … [Read more...] about Turing Pharmaceuticals announces that it has raised $90 million
Breo Ellipta approved for the treatment of asthma in Canada
GSK and Theravance, Inc. have announced that the Breo Ellipta fluticasone furoate/vilanterol DPI has been approved in Canada in 100/25 mcg and 200/25 mcg versions for the treatment of asthma in patients aged 18 years and older. Breo Ellipta was approved in Canada for the treatment of COPD in July 2013. Theravance, Inc. President and CEO Michael W. Aguiar … [Read more...] about Breo Ellipta approved for the treatment of asthma in Canada
Lupin celebrates grand opening of Center of Excellence for Inhalation Research
Lupin Limited has officially opened its new Center of Excellence for Inhalation Research in Coral Springs, Florida with a ceremony officials from the city and the state of Florida. The new center will employ 45 OINDP specialists. Lupin CEO Vinita Gupta commented, "We are delighted to be making our mark in South Florida. With the talent and resources this state … [Read more...] about Lupin celebrates grand opening of Center of Excellence for Inhalation Research